Physician profile
Jasmine Walker
NPI 1093383747
$1,629.87
in general payments reported to CMS, 2019-2025
16 companies · $823 in 2025
The $823 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $807 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $363.33 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $265.87 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $138.06 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $134.37 | 2024 | Spravato, Invega, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $120.90 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $120.68 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $115.12 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $90.31 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Indivior INC. | $79.41 | 2024-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.02 | 2025 | Caplyta |
| Watermark Medical, INC. | $40.16 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.31 | 2024-2025 | Trintellix |
| Lilly USA, LLC | $25.07 | 2025 | Mounjaro |
| Novo Nordisk INC | $23.83 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $19.60 | 2025 | Airsupra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $13.83 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.